Two- and three-year results of the thrombolysis in myocardial infraction (TIMI) phaes II clinical trial

摘要: Abstract Objectives . This report describes the survival and reinfarction rates for 2- 3-year follow-up in Thrombolysis Myocardial Infarction (TIMI) Phase II clinical trial. Background Patients enrolled TIMI were randomly assigned to an invasive (1,681 patients) or a conservative (1,658 management strategy follow receipt of intravenous recombinant tissue-type plasminogen activator acute myocardial infarction. Methods Eligibility required presentation within 4 h onset symptoms at least 1-mV ST segment elevation two contiguous electrocardiographic leads. The group underwent cardiac catheterization 18 48 after study entry and, when appropriate, percutaneous transluminal coronary angioplasty artery bypass grafting. In these diagnostic revascularization procedures reserved recurrent spontaneous ischemia on low level exercise time hospital discharge. Results Complete 2-year data are available 3,187 patients (95.4%). Cumulative life-table death 17.6% 17.9% (p = NS) mortality was 8.9% 8.7% NS), respectively. 1,959 (90.1%) 2,174 3 years. Rates 21.0% 20.0% with 11.5% 11.0% this cohort, 1.3% 2nd year 1.7% 3rd from entry. Conclusions strategies resulted similar favorable outcomes 2 Mortality comparable. Deaths infrequent years